Thomson Reuters’ issue of “Practical Law China: What to Expect in 2024” features the views of a select panel of China law practitioners across a broad range of practice areas on the major legal developments they foresee in China in 2024 – and for their predictions on how these changes could impact clients going forward.
In the piece, life sciences partner Katherine Wang (Singapore) discussed the significance of China’s Human Genetic Resources (HGR) Regulations on the life sciences industry. “The HGR implementing rules eased regulatory oversight of basic research and clinical development on human biological materials, various provincial governments … announced favourable policies and issued detailed regulations to encourage investment in gene and cell therapies,” Katherine stated in the piece. “[A]s foreign investment is not yet allowed in this sector, these changes will most likely benefit Chinese companies that invest in gene and stem cell therapies,” she continued.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.